Stereochemistry | ABSOLUTE |
Molecular Formula | C37H43N5O9S.Pd |
Molecular Weight | 840.25 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Pd++].[H][C@@]1(CC)[C@@H](C)C2=CC3=C(C(C)=O)C(C)=C([N-]3)C=C4N=C(C(CC(=O)OC)=C5[N-]C(=CC1=N2)C(C)=C5C(=O)NCCS(O)(=O)=O)[C@@]([H])(CCC(O)=O)[C@]4([H])C
InChI
InChIKey=MZRDSGWDVDESRC-VNWQTDIGSA-L
InChI=1S/C37H45N5O9S.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);/q;+2/p-2/t17-,18+,22-,23+;/m1./s1
Padeliporfin is a vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with antineoplastic activity. After administration, the drug is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Padeliporfin is approved in Europe for the treatment of adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate and is marketed under tradename TOOKAD.